BioStock: Follicum takes a step closer to phase III entering 2021

A productive 2020 for Follicum is capped off by the completion of patient recruitment for its phase II hair growth study for determining the best dose and treatment duration of candidate FOL-005. BioStock spoke with Follicum’s CEO Jan Alenfall to get his impressions on the company’s highlights for 2020 and what to expect in 2021

Read the full interview with Follicum's CEO Jan Alenfall at biostock.se:

https://www.biostock.se/en/follicum-takes-a-step-closer-to-phase-iii-entering-2021/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se